Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experience

BACKGROUND: The repeated waves of the COVID-19 pandemic have highlighted the necessity to optimize vaccine responses in immunocompromised populations. We investigated the safety and immunogenicity of a third, booster, dose of the Pfizer BNT162b2 vaccine in heart transplant (HT) patients. METHODS: Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Peled, Yael, Ram, Eilon, Lavee, Jacob, Segev, Amit, Matezki, Shlomi, Wieder-Finesod, Anat, Halperin, Rebecca, Mandelboim, Michal, Indenbaum, Victoria, Levy, Itzchak, Sternik, Leonid, Raanani, Ehud, Afek, Arnon, Kreiss, Yitshak, Lustig, Yaniv, Rahav, Galia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Society for Heart and Lung Transplantation. 2022
Materias:
Original Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8397500/
https://www.ncbi.nlm.nih.gov/pubmed/34565682
http://dx.doi.org/10.1016/j.healun.2021.08.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8397500/
https://www.ncbi.nlm.nih.gov/pubmed/34565682
http://dx.doi.org/10.1016/j.healun.2021.08.010

Ejemplares similares